ROG.VX: Esbriet survival analysis is all-cause but not all patient mortality

Several survival analyses of Roche new anti-Pulmonary fibrosis drug Esbriet show that despite having a modest benefit in select patients Esbriet does not improve overall survival. New pooled analyses from the European Respiratory Society meeting suggests a survival benefit is seen now, however a closer look at the analysis suggests this may be not be a complete picture

Login in to download pdf